Over the past year, Exploration of Targeted Anti-tumor Therapy has achieved an increasing impact and larger number of citations. We sincerely thank everyone's great support! At the beginning of 2023, we are thrilled to announce and recognize the winners of "Highly Cited Paper Award 2022" to show our appreciation to those authors.

Criteria for selection and award:

● Original Articles and Reviews published in 2020-2022;

● Both regular and special issue submissions are considered;

● Citations are counted according to Web of Science (WOS) in 2022;

● Prize for the author team: 300-1,000 USD, certificate of "Highly Cited Paper Award";

● Prize for the corresponding Guest Editor(s): 100-300 USD.

Winning Papers:

★Current strategies for the design of PROTAC linkers: a critical review

  Robert I. Troup, Charlene Fallan*, Matthias G. J. Baud*

  Special Issue: Proteolysis Targeting Chimera (PROTAC)

★The impact of tumour pH on cancer progression: strategies for clinical intervention

  Carol Ward, James Meehan, Mark E Gray, Alan F Murray, David J Argyle, Ian H Kunkler, Simon P Langdon*

★The clinical advances of proteolysis targeting chimeras in oncology

  Hao Xie*, Junjia Liu, Diego M. Alem Glison, Jason B. Fleming

  Special Issue: Proteolysis Targeting Chimera (PROTAC)

Congratulations! We believe these articles will be more shining in the future.

In the following year, we will continue to set "Highly Cited Paper Award" to recognize the related authors. On behalf of the Editorial Board and Editorial Office, we warmly welcome more outstanding researchers to participate in and contribute to the journal. Our thriving journal is always open to you!